Hinova Pharmaceuticals, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Hinova Pharmaceuticals, Inc.

Why is Hinova Pharmaceuticals, Inc. ?

Poor Management Efficiency with a low ROCE of 0%

The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward

Poor long term growth as Net Sales has grown by an annual rate of 141.36% and Operating profit at 13.38% over the last 5 years

Positive results in Jun 25

OPERATING CASH FLOW(Y) Highest at CNY -124.69 MM
ROCE(HY) Highest at -13.32%
OPERATING PROFIT(Q) Highest at CNY -35.74 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 60.42%, its profits have risen by 30.1%

Market Beating Performance

The stock has generated a return of 60.42% in the last 1 year, much higher than market (China Shanghai Composite) returns of 15.14%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Hinova Pharmaceuticals, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

No Data Found

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

141.36%

EBIT Growth (5y)

13.38%

EBIT to Interest (avg)

-165.23

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.65

Sales to Capital Employed (avg)

0.00

Tax Ratio

0.01%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.04

EV to EBIT

-1.69

EV to EBITDA

-1.75

EV to Capital Employed

1.16

EV to Sales

24.57

PEG Ratio

Dividend Yield

ROCE (Latest)

-68.60%

ROE (Latest)

-14.48%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bearish

Bullish

Moving Averages

Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

20What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY -124.69 MM

ROCE(HY)

Highest at -13.32%

OPERATING PROFIT(Q)

Highest at CNY -35.74 MM

RAW MATERIAL COST(Y)

Fallen by -8,689% (YoY

NET SALES(9M)

Higher at CNY 13.06 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 0.42%

PRE-TAX PROFIT(Q)

Highest at CNY -30.27 MM

NET PROFIT(Q)

Highest at CNY -30.27 MM

EPS(Q)

Highest at CNY -0.3

-3What is not working for the Company

INVENTORY TURNOVER RATIO(HY)

Lowest at 11.43%

Here's what is working for Hinova Pharmaceuticals, Inc.

Net Sales

At CNY 13.06 MM has Grown at 48,954.06%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (CNY MM)

Operating Cash Flow

Highest at CNY -124.69 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Operating Profit

Highest at CNY -35.74 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Operating Profit trend is quite positive

Operating Profit (CNY MM)

Pre-Tax Profit

Highest at CNY -30.27 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

Highest at CNY -30.27 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY -0.3

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Debtors Turnover Ratio

Highest at 0.42%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Net Sales

Higher at CNY 13.06 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the nine month period the company has already crossed sales of the previous twelve months

Net Sales (CNY MM)

Raw Material Cost

Fallen by -8,689% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Hinova Pharmaceuticals, Inc.

Inventory Turnover Ratio

Lowest at 11.43%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio